Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The FDA authorized fruit-flavored vapes for adult consumers, reversing years of aggressive regulatory efforts to restrict flavored vaping products. The decision followed pressure from President Trump on FDA leadership. This move eliminates restrictions on flavored e-cigarettes that had been in place to discourage youth vaping.
The Trump administration's changes to CDC vaccine guidance resulted in the loss of recommendations for several vaccines including flu and Covid shots. A judge's stay on these changes created uncertainty about vaccine access in some states, while a halted vaccines committee prevents new recommendations from being made. This directly impacts Americans' access to preventive vaccines and future vaccine development.
The Trump administration redirected the Title X family planning program to de-emphasize hormonal birth control provision at health clinics. This policy shift changes the program's core focus despite clinics receiving delayed funding. The change directly impacts women's access to contraception through federally-funded clinics nationwide.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
Executive Order 14336 directs the establishment and filling of a Strategic Active Pharmaceutical Ingredients Reserve to strengthen domestic pharmaceutical supply chains. The order aims to reduce U.S. dependence on foreign sources for critical drug components and improve resilience against supply disruptions. Americans may see increased availability and potentially lower costs for essential medications through enhanced domestic pharmaceutical production capacity.
The Drug Enforcement Administration announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related kratom-derived compounds as Schedule I controlled substances, placing them in the same category as heroin and LSD. The action would eliminate legal access to products containing these substances and criminalize possession. The policy affects thousands of Americans who use kratom products for pain management and wellness purposes.
Health Secretary Robert F. Kennedy Jr. restructured the Advisory Committee on Immunization Practices (ACIP), a key federal vaccine policy body. Senate Democrats launched an investigation into the legal and public health consequences of the panel changes. The action affects vaccine approval processes and guidance affecting millions of Americans.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
Executive Order 14293 signed on May 5, 2025, removes regulatory barriers to increase domestic production of critical medicines in the United States. The order streamlines FDA approval processes and reduces compliance requirements for pharmaceutical manufacturers. This aims to reduce American dependence on foreign drug sources and lower medication costs for consumers.
The Trump administration ousted FDA acting drug chief Dr. Tracy Beth Høeg, acting vaccines chief Katherine Szarama, and chief of staff Jim Traficant in a major leadership shake-up. The agency now lacks a permanent commissioner and stable leadership during critical drug approval and vaccine oversight functions. The departure of experienced regulators weakens FDA capacity to evaluate drug safety and vaccine efficacy during a period of potential regulatory rollback.